At what enterprise value was LABORATOIRES ANIOS acquired in 2013?

During the acquisition of LABORATOIRES ANIOS by ARDIAN in 2013, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LABORATOIRES ANIOS when it was acquired by ARDIAN?

The estimated EV/EBITDA multiple for LABORATOIRES ANIOS is in the range of 5x - 12x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was LABORATOIRES ANIOS acquired by ARDIAN?

LABORATOIRES ANIOS was acquired by ARDIAN in 2013.

What was the revenue of LABORATOIRES ANIOS at the time of the deal?

The revenue of LABORATOIRES ANIOS at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LABORATOIRES ANIOS during the acquisition?

LABORATOIRES ANIOS's EBITDA is estimated to be in the range of 25M - 50M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LABORATOIRES ANIOS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABORATOIRES ANIOS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/ardian-et-bertrand-et-thierry-letartre-concluent-la-cession-des-laboratories

← DATABASE

Home Database Healthcare & PharmaLABORATOIRES ANIOS

10/2013

LABORATOIRES ANIOS acquired by ARDIAN

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 300M - 700M EUR

Context

Air Liquide has entered into exclusive negotiations to sell its 66% majority stake in Laboratoires Anios to a consortium comprised of Ardian and the founding Letartre brothers, Bertrand and Thierry. This transaction represents a strategic spin-off for Air Liquide, allowing the industrial gas giant to refocus its hygiene activities exclusively on its German subsidiary, Schülke & Mayr. The acquisition is structured with an LBO featuring a senior debt facility and an important CAPEX line to fund future growth. The financing reflects a leverage effect of 4.0x to 5.0x EBITDA. The primary strategic rationale for the new ownership is to accelerate Anios's international footprint, particularly through M&A opportunities in emerging markets such as Brazil, India, and China, moving the company toward a more globalized operational model.

LABORATOIRES ANIOS, which reported an EBITDA margin of LOGIN in 2012, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded by the Letartre family and based in Lille, Laboratoires Anios is a European leader in the hygiene and disinfection sector for hospitals, clinics, and industrial environments. The company provides holistic solutions for medical device disinfection, including endoscope washer-disinfectors, as well as products for the food and professional cleaning industries. Its business model integrates high-intensity R&D with specialized chemical manufacturing across international sites.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2012

2011

Other operations with LABORATOIRES ANIOS

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
02/2017	ECOLAB	LABORATOIRES ANIOS	FRANCE	Life Sciences	Ecolab has completed the acquisition of 100% of Laboratoires Anios from Ardian and the Letartre family. This transaction represents a definitive exit for the private equity firm Ardian, which had supported the founding family in a 2013 LBO following a previous ownership cycle by Air Liquide

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABORATOIRES ANIOS by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: laboratoires anios

Acquirer: ardian